Thomas M. Hennigan
Thank you, Justin. Today, I'll begin with an overview of our second quarter financial results, then I'll discuss portfolio performance before concluding with detail on our balance sheet position. Total investment income for the second quarter was $67 million, up significantly from prior quarter as a result of a higher investment portfolio balance attributable to the merger with CSL III which closed at the end of Q1,and the purchase of Credit Fund II in mid- February. Total expenses of $39 million also increased versus prior quarter, primarily as a result of higher interest expense from a higher average outstanding debt balance, along with higher management and incentive fees driven by growth in the size of the portfolio. The result was net investment income for the second quarter of $28 million or $0.39 per share on both a GAAP basis and after adjusting for asset acquisition accounting, which excludes the amortization of the purchase price premium from the CSL III merger and the purchase price discount associated with the consolidation of Credit Fund II. This quarter's earnings, which demonstrates the first full quarter of the combined CGBD and CSL III portfolios, decreased by about $0.01 per share as we continue to work towards achieving our target leverage levels at both CGBD and the MMCF JV. As previewed last quarter, the earnings power of the combined portfolio remains in the same range as precombination Q1 CGBD earnings. Our Board of Directors declared the dividend for the third quarter of 2025 at a level of $0.40 per share, which is payable to stockholders of record as of the close of business on September 30. This dividend level represents an attractive yield of over 11% based on the recent share price. In addition, we currently estimate we have $0.89 per share of spillover income generated over the last 5 years, so we feel comfortable in our ability to maintain the quarterly dividend. On valuations, our total aggregate realized and unrealized net loss for the quarter was about $14 million or $0.19 per share, partially attributable to unrealized markdowns on select underperforming investments. Turning to credit performance. We continue to see overall stability in credit quality across the portfolio with some underperformance in a handful of names. On the metrics, the risk rating distribution remained relatively stable with one name added to nonaccrual during the quarter, increasing nonaccruals to 2.1% of total investments at fair value. At the beginning of July, we closed the successful restructuring of Maverick which, all else equal, decreases nonaccruals to 1% of total investments at fair value on a pro forma basis. And while our nonaccrual rates may fluctuate from period to period, we're confident in our ability to leverage the broader Carlyle network to achieve maximum recoveries for underperforming borrowers. Moving to our credit fund. As previewed last quarter, we've been focused on maximizing both asset growth and returns at the MMCF JV over the last few quarters. As you can see from our investment activity, we continue to bolster the asset base and we expect the MMCF JV dividend to achieve a run rate of mid-teens ROE. Separately, we continue to work on optimizing our nonqualifying asset capacity and anticipate using this flexibility going forward for other strategic partnerships. I'll finish by touching on our financing facilities and leverage. In July, we closed a small upsize to our primary revolving credit facility, increasing total commitments to $960 million in total. At quarter end, statutory leverage is about 1.1x, towards the midpoint of our target range, and given our current strong liquidity profile and targeted incremental sales to the MMCF JV, we're well positioned to benefit from the expected pickup in deal volume in future quarters. With that, I'll turn the call back over to Justin.